Yumanity Therapeutics
Biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Launch date
Employees
Market cap
AUD31.7m
Enterprise valuation
AUD19m (Public information from Dec 2022)
Share price
$1.89 YMTX
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $51.0m | Series A | |
| N/A | N/A | IPO | |
| N/A | $31.1m | Post IPO Equity | |
| N/A | $21.6m | Series C | |
$33.6m | Late VC | ||
* | N/A | Acquisition | |
| Total Funding | AUD164m | ||
Related Content
Recent News about Yumanity Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.